NEW YORK (GenomeWeb) — Response Genetics has been warned by Nasdaq that it is not in compliance with a rule to remain listing on the Nasdaq Capital Market, the company recently disclosed in a document filed with the US Securities and Exchange Commission.
Nasdaq sent a letter to the firm in late November saying it does not meet a listing requirement calling for a minimum of $2.5 million stockholders' equity. For the third quarter ended Sept. 30, Response Genetics had shareholders' equity of about $2.0 million, according to the firm's Form 10-Q.
The company has 45 days to submit a plan to regain compliance with the Nasdaq listing rule, and said in the SEC document that it is working on such a plan. Its deadline for submitting the plan is Jan. 8, 2015.